Oppenheimer analyst Leland Gershall reiterated an Outperform rating and $10.00 price target on Trevi Therapeutics (NASDAQ: TRVI), following the company's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE